{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:24:27Z","timestamp":1762917867101},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00105-017-4109-y","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T03:57:48Z","timestamp":1515729468000},"page":"674-680","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Initial nicht erkannte De-novo-Psoriasis getriggert durch Nivolumab bei metastasiertem Zungengrundkarzinom"],"prefix":"10.1007","volume":"69","author":[{"given":"S.","family":"Troyanova-Slavkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Eickenscheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Dumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kowalzick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"4109_CR1","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/bjd.12519","volume":"169","author":"R Anforth","year":"2013","unstructured":"Anforth R, Blumetti TC, Clements A et\u00a0al (2013) Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a\u00a0cohort of patients on BRAF inhibitors. Br J Dermatol 169:1310\u20131313","journal-title":"Br J Dermatol"},{"key":"4109_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","volume":"35","author":"J Dulos","year":"2012","unstructured":"Dulos J, Carven GJ, van Boxtel SJ et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J\u00a0Immunother 35:169\u2013178","journal-title":"J Immunother"},{"issue":"8","key":"4109_CR3","first-page":"19","volume":"23","author":"MD Elosua-Gonzales","year":"2017","unstructured":"Elosua-Gonzales MD, Pampin-Franco A et al (2017) A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy. Dermatol Online\u00a0J 23(8):19","journal-title":"Dermatol Online J"},{"key":"4109_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et\u00a0al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N\u00a0Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"4109_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14011","author":"G Jeudy","year":"2016","unstructured":"Jeudy G, Pahm-Ledard A, Perol M et al (2016) Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol. \n                    https:\/\/doi.org\/10.1111\/jdv.14011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"4109_CR6","first-page":"17","volume":"350","author":"HT Jin","year":"2011","unstructured":"Jin HT, Ahmed R, Okazaki T (2011) Role of PD-1 in regulating T\u2011cell immunity. Curr Top Microbiol Immunol 350:17\u201337","journal-title":"Curr Top Microbiol Immunol"},{"key":"4109_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","volume":"43","author":"G Jour","year":"2016","unstructured":"Jour G, Glitza IC, Ellis RM et al (2016) Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a\u00a0report on bullous skin eruptions. J\u00a0Cutan Pathol 43:688\u2013696","journal-title":"J Cutan Pathol"},{"key":"4109_CR8","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1111\/jdv.13336","volume":"30","author":"Y Kato","year":"2016","unstructured":"Kato Y, Otsuka A, Miyachi Y, Kabashima K (2016) Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J\u00a0Eur Acad Dermatol Venereol 30:e89\u201391","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"4109_CR9","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jtho.2017.05.005","volume":"12","author":"M Khunger","year":"2017","unstructured":"Khunger M, Calabrese C, Kontzias A, Velcheti V (2017) To treat or not to treat: role of immunotherapy in patients with concomitant diagnosis of advanced-stage non-small cell lung cancer and psoriasis. J\u00a0Thorac Oncol 12:e147\u20139","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4109_CR10","first-page":"54","volume":"33","author":"K Kieseritzky von","year":"2017","unstructured":"von Kieseritzky K (2017) Kutane Nebenwirkungen der Immuntherapie. Hautnah Dermatologie 33(3):54","journal-title":"Hautnah Dermatologie"},{"key":"4109_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jaci.2015.11.021","volume":"137","author":"JH Kim","year":"2016","unstructured":"Kim JH, Choi YJ, Lee BH et al (2016) Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1\u2011high T\u00a0cells. J\u00a0Allergy Clin Immunol 137:1466\u20131476","journal-title":"J Allergy Clin Immunol"},{"key":"4109_CR12","doi-asserted-by":"publisher","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T et\u00a0al (2015) Epidemiology of psoriasis and palmoplantar pustulosis: a\u00a0nationwide study using the Japanese national claims database. BMJ Open 5:e6450","journal-title":"BMJ Open"},{"key":"4109_CR13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","volume":"5","author":"S Law-Ping-Man","year":"2016","unstructured":"Law-Ping-Man S, Martin A, Briens E et al (2016) Psoriasis and psoriatic arthritis induced by nivolumab in a\u00a0patient with advanced lung cancer. Rheumatology (Oxford) 5:2087\u20132089","journal-title":"Rheumatology (Oxford)"},{"key":"4109_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","volume":"71","author":"CW Lynde","year":"2014","unstructured":"Lynde CW, Poulin Y, Vender R et\u00a0al (2014) Interleukin 17A: toward a\u00a0new understanding of psoriasis pathogenesis. J\u00a0Am Acad Dermatol 71:141\u2013150","journal-title":"J Am Acad Dermatol"},{"key":"4109_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2340\/00015555-2212","volume":"96","author":"N Matsumura","year":"2016","unstructured":"Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T (2016) Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 96:259\u2013260","journal-title":"Acta Derm Venereol"},{"key":"4109_CR16","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/jdv.13818","volume":"31","author":"Y Nonomura","year":"2017","unstructured":"Nonomura Y, Otsuka A, Ohtsuka M (2017) ADAMTSL5 is upregulated in melanoma tissues in patients with idiopatic psoriasis vulagris induced by nivolumab. J\u00a0Eur Acad Dermatol Venereol 31:e100\u2013101","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"4109_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2177\/jsci.40.95","volume":"40","author":"N Okiyama","year":"2017","unstructured":"Okiyama N, Tanaka R (2017) Varied immuno-related adverse events induced by immune-check point inhibitors\u2014Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6. Nihon Rinsho Meneki Gakkai Kaishi 40:95\u2013101","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"4109_CR18","doi-asserted-by":"crossref","first-page":"232470961667431","DOI":"10.1177\/2324709616674316","volume":"4","author":"SD Phadke","year":"2016","unstructured":"Phadke SD, Ghabour R, Swick BL et\u00a0al (2016) Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease. J\u00a0Investig Med High Impact Case Rep 4:2324709616674316","journal-title":"J. Investig. Med. High. Impact. Case Rep."},{"issue":"1","key":"4109_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","volume":"153","author":"A Pedoeem","year":"2014","unstructured":"Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ (2014) Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153(1):145\u2013152. \n                    https:\/\/doi.org\/10.1016\/j.clim.2014.04.010","journal-title":"Clin Immunol"},{"issue":"4","key":"4109_CR20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s10753-015-0132-2","volume":"38","author":"M Peled","year":"2015","unstructured":"Peled M, Strazza M, Azoulay-Alfaguter I, Mor A (2015) Analysis of programmed death-1 in patients with psoriatic arthritis. Inflammation 38(4):1573\u20131580. \n                    https:\/\/doi.org\/10.1007\/s10753-015-0132-2","journal-title":"Inflammation"},{"key":"4109_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/apm.12658","volume":"125","author":"J Ruiz-Ba\u00f1obre","year":"2017","unstructured":"Ruiz-Ba\u00f1obre J, Abdulkader I, Anido U et al (2017) Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. Acta Pathol Microbiol Immunol Scand 125:259\u2013263","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"key":"4109_CR22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2146\/ajhp150235","volume":"72","author":"A Rounds","year":"2015","unstructured":"Rounds A, Kolesar J (2015) Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. Am J Health Syst Pharm 72:1851\u20131855","journal-title":"Am J Health Syst Pharm"},{"key":"4109_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ad.2015.07.012","volume":"107","author":"A Sahuquillo-Torralba","year":"2016","unstructured":"Sahuquillo-Torralba A, Ballester-Sanchez R et al (2016) Pembrolizumab: a\u00a0new drug that can induce exacerbations of psoriasis. Actas Dermosifiliogr 107:264\u2013266","journal-title":"Actas Dermosifiliogr"},{"key":"4109_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1610-0387.2005.05509.x","volume":"3","author":"C Seebacher","year":"2005","unstructured":"Seebacher C, Korting HC, Abeck D et\u00a0al (2005) Tinea der freien Haut. J\u00a0Dtsch Dermatol Ges 3:921\u2013926","journal-title":"J Dtsch Dermatol Ges"},{"key":"4109_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L et al (2016) Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254\u2013263","journal-title":"Curr Opin Oncol"},{"key":"4109_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","volume":"7","author":"R Sundar","year":"2015","unstructured":"Sundar R, Cho BC, Brahmer JR, Soo RA (2015) Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7:85\u201396","journal-title":"Ther Adv Med Oncol"},{"key":"4109_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","volume":"19","author":"M Sznol","year":"2013","unstructured":"Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021\u20131034","journal-title":"Clin Cancer Res"},{"key":"4109_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a\u00a0systematic review and meta-analysis. J\u00a0Clin Oncol 33:773\u2013781","journal-title":"J Clin Oncol"},{"key":"4109_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK et\u00a0al (2013) Nivolumab plus ipilimumab in advanced melanoma. N\u00a0Engl J Med 369:122\u2013133","journal-title":"N Engl J Med"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-017-4109-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T20:40:44Z","timestamp":1547239244000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-017-4109-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4109"],"URL":"https:\/\/doi.org\/10.1007\/s00105-017-4109-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"12 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Troyanova-Slavkova, L.\u00a0Eickenscheidt, K.\u00a0Dumann und L.\u00a0Kowalzick geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}